Z-VAD-FMK

For research use only.

Catalog No.S7023

569 publications

Z-VAD-FMK Chemical Structure

CAS No. 187389-52-2

Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

Size Price Stock Quantity  
USD 117 In stock
USD 470 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Z-VAD-FMK has been cited by 569 publications

Purity & Quality Control

Choose Selective Caspase Inhibitors

Biological Activity

Description Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.
Features A key compound for apoptosis studies.
Targets
Pan-caspase [1]
(THP.1, Jurkat T-cells)
In vitro

Z-VAD-FMK (10 mM) inhibits apoptosis in THP.1 cells. Z-VAD-FMK (10 μM) inhibits activation of PARP protease activity in control THP.1 cell lysates. Z-VAD-FMK (10 mM) inhibits the processing of CPP32 in intact THP.1 and Jurkat cells. [1] Z-VAD-FMK (50 μM) cotreatment abolishes the apoptotic morphology of camptothecin-treated HL60 cells. Z-VAD-FMK (50 μM) blocks camptothecin-induced DNA fragmentation in HL60 cells. [2] Z-VAD-FMK (50 μM) inhibits cell death following dSMN dsRNA-induced apoptosis in S2 cells. Z-VAD-FMK (50 μM) increases the percentage of transfected cells surviving from 26% to 63% in S2 cells. [3] Z-VAD-FMK (> 100 μM) enhances TNFα-induced neutrophil apoptosis, lower concentrations (1-30 μM) completely blocks TNFα-stimulated apoptosis in human neutrophils. [4] Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes. Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes detected with the TUNEL assay. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
GC1a MYLBdI9xfG:|aYOgRZN{[Xl? MWS1NO69VQ>? MnjuNlRp MmDVbY5lcWOjdHXzJIEheHKxdHXjeIl3\SCnZn\lZ5Qh[WejaX7zeEBmfG:yb4Pp[IU> NH73W3kzPjF4OUC3OS=>
HGL5 NV21PJNISXCxcITvd4l{KEG|c3H5 M4[5[FUx|ryP Mn3GNlRp NGThXZFqdmSrY3H0[ZMh[SCycn;0[YN1cX[nIHXm[oVkfCCjZ3HpcpN1KGW2b4Dvd4ll\Q>? MnqyNlYyPjlyN{W=
HepG2 M4e1UWFxd3C2b4Ppd{BCe3OjeR?= NXvjcphQOjEQvF2= NU\l[Wh[OWh? MXnheJRmdnWjdHXkJJRp\SCjcH;weI91cWNiaX7keYN1cW:wIH;mJGlKUS1zMNMg NIrzRmczPjF4NEe5OS=>
BEL-7402 MnTuRZBweHSxc3nzJGF{e2G7 M{LNTVIx|ryP NELxWY8ycA>? MWfheJRmdnWjdHXkJJRp\SCjcH;weI91cWNiaX7keYN1cW:wIH;mJGlKUS1zMNMg Mn7pNlYyPjR5OUW=
CEF NHKyVVhMcW6jc3WgRZN{[Xl? NID2[VMxNDN|LE[3MFExOM7:TR?= NVW1RXRPOTWvaX6= MUfkc5dvNXKnZ4XsZZRmeyCSUjDlcpp6dWViYXP0bZZqfHlidH:gOFDwxIViYYSgNVAx|ryP NYnZUYZ{OjZzMEKzN|k>
SP2/0 Mnj6RZBweHSxc3nzJGF{e2G7 NFzNeoYyODEQvF2= NF7Y[4kycA>? M3y3cWROW09? NGnUNlhjdG:la4OgeIhmKGGyb4D0c5NqeyCxZjDTVFIwOCClZXzsdy=> MX6yOlA4PDd|Mh?=
HUVEC-2c MkiyRZBweHSxc3nzJGF{e2G7 MnfmOVDPxE1? NYrUS2tSPmh? M1z3fIRm[3KnYYPl[EB1cGVib4itUGRNNWmwZIXj[YQh[XW2b4DoZYd6 NXvJfG82OjZyMkG3Nlk>
U1 MXTBdI9xfG:|aYOgRZN{[Xl? NUL4[odWOC1zMEFOwG0> NXfsfGNOOmh? NXiwW|RPemWmdXPld{BlenWpLXnu[JVk\WRiYYDvdJRwe2m|IHHu[EB{fWK|ZYH1[Y51KEiLVj2xJJJmeGyrY3H0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NHf0XmwzPTl6MEm0Ni=>
ACH-2 Mo\ORZBweHSxc3nzJGF{e2G7 MkXHNE0zODEQvF2= NV75NHU4Omh? MlvGdoVlfWOnczDkdpVoNWmwZIXj[YQh[XCxcITvd4l{KGGwZDDzeYJ{\XG3ZX70JGhKXi1zIILldIxq[2G2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NYj1OW5vOjV7OEC5OFI>
U1 NHfPd5pMcW6jc3WgRZN{[Xl? M{\t[FExOM7:TR?= MWGybC=> NF;US2lqdmirYnn0d{Bk[XOyYYPlMVM> Mn3kNlU6QDB7NEK=
A549/V16 NYrkfpo5SXCxcITvd4l{KEG|c3H5 MWe1NO69VQ>? MmrQNYg> MoLwdoVxemW|c3XzJHRIN1SPLXnu[JVk\WRiYYDvdJRwe2m| MljHNlU6PDZyM{O=
SGN NIrNWVFCeG:ydH;zbZMhSXO|YYm= MnPMNlBuVQ>? NGTTWJA1QGh? NIf0OGJp[XNibn:gbY5ndHWnbnPlJI9vKEGLRjygZ4FteGGrbjDlfJBz\XO|aX;uJI9zKGOnbHygZZBweHSxc3nz NEDL[XEzPTh5NE[zNy=>
HCT116  NVTmSYRDSXCxcITvd4l{KEG|c3H5 M3jMSFUx|ryP MXOybC=> M2KwTYlvcGmkaYTzJJRp\SClZXzsJIRm[XSqIHnu[JVk\WRiYomgSGRXWA>? NXjKc|NxOjV6Nki4NVg>
DTK-SME Mmi2RZBweHSxc3nzJGF{e2G7 NHu3b242OM7:TR?= NH\JWHgzcA>? NV[5fIFkTE2VTx?= MlrCdIFzfGmjbHz5JIlvcGmkaYTzJJRp\SCjcH;weI9{cXNiaX7keYNm\CCkeTDieZBqfmGlYXnu[S=> M3vNW|I2QDR|OEm3
HL-60 MYfBdI9xfG:|aYOgRZN{[Xl? NVKzU|QzPTEQvF2= NHPlUVU1QGh? MlvwdoVlfWOnczDj[YxtKGSnYYToJINifXOnZDDifUBUU0lvSVmgeJJm[XSvZX70xsA> NFfBXYQzPTh{NEC0Ny=>
U937 MVjBdI9xfG:|aYOgRZN{[Xl? M{DhW|Ux|ryP Mo\DOFhp MmP1doVlfWOnczDj[YxtKGSnYYToJINifXOnZDDifUBUU0lvSVmgeJJm[XSvZX70xsA> MVmyOVgzPDB2Mx?=
A549 M3nTUWFxd3C2b4Ppd{BCe3OjeR?= NIrZOGEzOCEQvF2= NWPvNI1mOjSq MonPdoVlfWOnczDj[YxtKGSnYYToJINifXOnZDDifUBJTkOSIITy[YF1dWWwdB?= NH:0NYYzPTd7NEG0PS=>
HeLa NWT0VmtuSXCxcITvd4l{KEG|c3H5 MmrzNVDPxE1? Mnj5OFhp NE\kXoJl\WOuaX7ld{B1cGVicnH0[UBw\iCjcH;weI9{cXNiZILhcYF1cWOjbHz5 M1ixRlI2Pzd{NUS1
SGC-7901 MkjGRZBweHSxc3nzJGF{e2G7 NWfDemtbOjEEoN88US=> MmDFNYg> MWnpcohq[mm2czD0bIUh[2WubDDk[YF1cCCrbnT1Z4VlKGK7IH;4ZYxqeGyjdHnu NYi0SYwzOjV5NkewO|Y>
MCF-7 MYTBdI9xfG:|aYOgRZN{[Xl? NYTPcog2OTEQvF2= NX33T41oOmh? NW\VXYZbcW6qaXLpeJMhfGinIHPlcIwh\GWjdHigbY5lfWOnZDDifUA{Sg>? MVSyOVczOjFzNB?=
A549 M2TvUGFxd3C2b4Ppd{BCe3OjeR?= MorVNVAh|ryP NEHSRm4zPGh? NVTieIU4TE2VTx?= Mmr6dJJwdW:2ZYOgTGJENXS{ZXH0[YQhSTV2OTDj[YxtKHO3co\peoFtKCZiYYT0[Y52[XSnczD0bIUh[2ynYY\l[EBRSVKSIHX4dJJme3Orb36= Mk\pNlU3QDN3Nki=
U87 NYn1UmIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUi1NO69VQ>? MlTWNYg> NVznToFUemWlb4\ldpMh[2WubDDndo94fGhiZoLvcUBVVVpidILlZZRu\W62 NXPpWW45OjV4OEG2Olg>
Neocortical Neuron NEfGdpJP\XW{b4TvfIlkcXS7IFHzd4F6 NVvaSpN6OTByzszN MkHjNYg> MVnhcpRi\2:waYrld{BJd2mjbXnk[UBCNUmwZIXj[YQhVmW3cn;0c5hq[2m2eR?= NHXLR4YzPTZ5NUCwNS=>
Primary human placental cytotrophoblasts NXrmUWgySXCxcITvd4l{KEG|c3H5 NVvvToFnOzEQvF2= NF3hbY0zPGh? NXu2XnJPTE2VTx?= M2\HepJmfmW{c3XzJJRp\SCrbnjpZol1cW:wIH;mJFEy|rJvSGPENkBjgSC2cnnjcI9{[W8EoB?= M{LxTlI2PjR{NUmy
MM MnHrRZBweHSxc3nzJGF{e2G7 NVTLN2luPTEQvF2= MU[yNI1qdg>? M4rkVJBienSueTDpcohq[mm2czDTTGsucW6mdXPl[EAh[2WubDDk[YF1cA>? M1TOO|I2PTNyMEm4
DLD1 M3K0SGFxd3C2b4Ppd{BCe3OjeR?= MXiyNOKh|ryP NXSzc3JLOWh? M2Pae5BienSueTDy[ZZmenOnczDj[YxtKGGyb4D0c5NqeyClYYXz[YQh[nliV2PQNS=> NXvHWoFvOjV3MkSyOFY>
MDA-MB-231 NEj1NmxEgXSxdH;4bYNqfHliQYPzZZk> MYixNO69VQ>? NV7mSHVqOWh? M33yR4F2\22nboTzJINmdGxiZHXheIgh[W[2ZYKgR2hWSSC2cnXheI1mdnR? NXrQbmZxOjV3MkG1NFE>
MKN28 M4\XbmFxd3C2b4Ppd{BCe3OjeR?= NWm5SYFrOTEQvF2= MlTnN|BucW5? NXP5eYRzTE2VTx?= NG\PO45qdmirYnn0d{BVVkZvzsGgdIx2eyCFSGitbY5lfWOnZDDhdI9xfG:|aYO= NIfIe|QzPTVzM{m2NC=>
HL-60 NEG1OY5EgXSxdH;4bYNqfHliQYPzZZk> NI\GO24yODEQvF2= MUWxbC=> M4\yTGROW09? NE[zXHXDqGmvcILveoV{KH[rYXLpcIl1gSCxZjDUR25Cey22cnXheIVlKGOnbHzz NWDIUmxQOjV3MEK5N|I>
AGS NVXm[oRNSXCxcITvd4l{KEG|c3H5 NXrUTVlMOTEQvF2= MmjwNYg> NEnITotxemW4ZX70d{BkfXKldX3pck1qdmS3Y3XkJINt\WG4YXflJI9nKGOjc4Dhd4UuOyxiLUisJIFv\CBvOTDwdo91\Wmwcx?= MmWzNlU1QTJ{MUS=
A549  MW\BdI9xfG:|aYOgRZN{[Xl? M2Hyc|Ex|ryP M32wbFI1cA>? NWHHTYgy[myxY3vzJGROSVNvaX7keYNm\CClbHXheoFo\SCxZjDjZZNx[XOnLUOgZY5lKFCDUmCgZY5lKGGyb4D0c5Rq[yClZXzsJIRm[XSq NXXZdmdnOjV2M{S5PFk>
INS-1 NF7ucpNCeG:ydH;zbZMhSXO|YYm= NVjHZW0zPTEQvF2= MmX0Oog> M1jjT2ROW09? MoHo[IVkemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIViemy7IHHwc5B1d3SrYzDj[Yxte8Li MUGyOVQ{ODh7Nx?=
Primary hepatocytes  NF3EfVdCeG:ydH;zbZMhSXO|YYm= M3;qWVUx|ryP M4C0[lE5cA>? MYnpcohq[mm2czDhdI9xfG:|aYOgc4YhcGWyYYTvZ5l1\XNiaX7keYNm\CCkeTDBZ5QhTCCjbnSgWG5HNc7z MX6yOVQxPzV|OB?=
L929-A  NYfJXpZFS3m2b4TvfIlkcXS7IFHzd4F6 MWmyNOKh|ryP NE\wSZUzPGh? NUXTcpVUcW6qaXLpeJMhXE6IzsGtbY5lfWOnZDDj[YxtKGSnYYTo M4LzRlI2Ozl6NUSw
L929-N MlXxR5l1d3SxeHnjbZR6KEG|c3H5 MUCyNOKh|ryP MnS5NlRp MX;lcohidmOnczDk[YF1cCC4aXGgZZV1d2O{aX7lJHRPTs7zIIDyc4R2[3Srb36= MoHSNlU{QTh3NEC=
Cytotoxicity Assay MWLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1PYS|Ix|ryP NGHBW|Q1QGh? NV;Rbm9KeHKndnXueEBOUE2GLXnu[JVk\WRiY3XscEBl\WG2aB?= NGrD[oYzPTN7MkGxOi=>
COS7 NXjSV5UzU2mwYYPlJGF{e2G7 M2DFWFEx|ryP MViyOIg> NXm1ZoJFcW6lcnXhd4V{KGOjc4Dhd4UhOy95IHHjeIl3cXSrZYO= Mnf2NlU{QDRyMkW=
COS7 MoC2RZBweHSxc3nzJGF{e2G7 NUHsSIR2OTEQvF2= MWm0PIg> Moe4dIFzfGmjbHz5JJBz\X[nboTl[EBHSzFyMT3pcoR2[2WmIHPlcIwh\GWjdHi= MlvyNlU{QDRyMkW=
A375 MmDPRZBweHSxc3nzJGF{e2G7 NXjqTlRIOzEQvF2= M2j6WFJp MnKxdJJmfmWwdIOgeIhmKGS{dXetbY5lfWOnZDDQRXJRKGOuZXH2ZYdm NGrvTm0zPTN5NkGxOS=>
A549 M4ezTGFxd3C2b4Ppd{BCe3OjeR?= NXjTXZlsPTEQvF2= MorvNlRp MojhdoV3\XK|ZYOgdoljd3OxbXWgZolw\2WwZYPpd{BidmRiYYDvdJRwe2m|IHPheZNm\CCkeTCgR4hqcm:wZ3Thci=> M1y2OFI2OzR7N{ix
A549 M4fpPGFxd3C2b4Ppd{BCe3OjeR?= M1W0V|IvPS1{Nd88US=> M1u0W|Fp Mnj6[IVkemWjc3XzJJRp\SCyb4D1cIF1cW:wIH;mJIFxd3C2b4TpZ{Bk\WyuczDk[ZBmdmRib36gZ49v[2WwdILheIlwdnN? M1e1XlI2OzR{NEK3
 NBL-W-S  MUTBdI9xfG:|aYOgRZN{[Xl? MUO1NO69VQ>? NGG5eYkycA>? MlPy[pVtdHlicnXzZ5VmeyClZXzsJJZq[WKrbHn0fUBi\nSncjDHRW5VNTZzIITy[YF1dWWwdB?= NYjDRmZjOjV|MkOyNlI>
Caki-1  MUjBdI9xfG:|aYOgRZN{[Xl? M2rSO|Qx|ryP M2TmeFQ5cA>? MnjqdoVlfWOnczD0bIUhdnWvYnXyJI9nKEGwbnX4bY4hXi2yb4PpeIl3\SClZXzsdy=> MXOyOVI4QTF7MR?=
769-P NU\PbIVZSXCxcITvd4l{KEG|c3H5 MUC0NO69VQ>? MljoOFhp NYDuOZBZemWmdXPld{B1cGViboXtZoVzKG:oIFHucoV5cW5iVj3wc5NqfGm4ZTDj[Yxtew>? NHXBRpYzPTJ5OUG5NS=>
H9c2 MYrBdI9xfG:|aYOgRZN{[Xl? NYLqOIRkPTEQvF2= NYjzdXM1OWh? NHfT[VhqdmirYnn0d{BFV1hvaX7keYNm\CClYYPwZZNmKDNiYXP0bZZifGmxbjDieZQhdm:2IITo[UBtd3O|IH;mJINmdGy| NX;xR2ZZOjV{OEO4NVk>
K562 M2PUUWFxd3C2b4Ppd{BCe3OjeR?= MlrHOVDPxE1? NXSybZo6PGh? M3\NPIlvcGmkaYTzJGpi[y2DLXnu[JVk\WRiY3XscEBieG:ydH;zbZM> M2rMd|I2OjRzNkG5
L929 NVmwcVg3SXCxcITvd4l{KEG|c3H5 M1zhUVEx|ryP MoXtOog> MoP3bY5lfWOnczDu[YNzd3C2b4Ppd{B4cXSqIGTOSi=> NV7jfnNkOjVzOUW2OlA>
A549 M{H1fWFxd3C2b4Ppd{BCe3OjeR?= MWGxNO69VQ>? NFvlUZA{cA>? MoXDdoVlfWOnczDj[YxtKGGyb4D0c5NqeyClYYXz[YQh[nliUGHR MkDoNlUyPjF4OUm=
MCF-7 MWrBdI9xfG:|aYOgRZN{[Xl? NGS5OpQzOM7:TR?= Mkn6Nog> NVTZd2ZY\GWlcnXhd4V{KEuGUj3zbXJPSS2rbnT1Z4VlKGGyb4D0c5Nqew>? Moe3NlUyQDJ{NEC=
OS MXPBdI9xfG:|aYOgRZN{[Xl? NFPqbXgzOC92MN88US=> Mn7QO|Jp M1TabYlvcGmkaYTzJG9UKGOnbHygeoli[mmuaYT5JJJm\HWldHnvckBjgSCFNjDj[ZJidWmmZR?= MoPFNlUyPTJ|OUm=
HUVECs NWLUcYc2SXCxcITvd4l{KEG|c3H5 MWWxNO69VQ>? Mo\DNog> MVdCpIlvcGmkaYTzJIFxd3C2b4Ppd{BidmRiZnHjbYxqfGG2ZYOgZZV1d3CqYXf5JIlvKESHTm[yMYlv\mWldHXkJGhWXkWFcx?= Mor2NlUyOzh5MEO=
EA.hy926 M3zzWmFxd3C2b4Ppd{BCe3OjeR?= MoDxNVDPxE1? M4\KeVJp NXLySZVVyqCrbnjpZol1eyCjcH;weI9{cXNiYX7kJIZi[2muaYTheIV{KGG3dH;wbIFogSCrbjDESW5XOi2rbn\lZ5Rm\CCHQT7ofVkzPg>? MnvWNlUyOzh5MEO=
Ebs NGrpXmhCeG:ydH;zbZMhSXO|YYm= MVuxNE0yODEQvF2= MXqyOIg> M{PKe:KhVU2WUzDn[Y5memG2aX;uJJJifGViZHXjdoVie2WmIHHzJJRp\SClb37j[Y51emG2aX;uJI9nKHpvVlHEMoZucyCrbnPy[YF{\WR? MlrlNlUyOzR6MUe=
Jurkat NV7vbJRCSXCxcITvd4l{KEG|c3H5 MUGyNO69VQ>? M2H2cFI1cA>? NE\rR5JFVVOR NEKx[Hpx[XK2aXHscJkhcW6qaXLpeEBk\WyuIHTlZZRpKG:oIFr1dotifCClZXzsd{BqdmS3Y3XkJIJ6KDFyMEW4MWY1KGOxbXLpcoVlKHerdHigWnBCyqB? M{fVdlI2OTJyN{Kz
K562 NIXyeWRCeG:ydH;zbZMhSXO|YYm= MVWwMlEuOc7:TR?= MnnZNYg> M3XDV4lvcGmkaYTzJINt\WG4YXflJI9nKEiVUEmwJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NX;aXIJjOjVzMUmxPFg>
IMR-32 MoCyRZBweHSxc3nzJGF{e2G7 NUHPV4dbPDEEoN88UeKh MlvCNog> NULPPIw2\GWlcnXhd4UhcW5iYYDvdJRwfGmlIHPlcIx{KGOxbYDhdoVlKHSxIGStNkB1d3irbh?= MXiyOVA5PDd3NR?=
RPMI 8226 NGP5NmxCeG:ydH;zbZMhSXO|YYm= MVWxNFDPxE1? NVuzdY9ROWh? Ml:zZYxud3O2IHPvcZBt\XSnbImgZoxw[2u|IHPlcIwh\GWjdHigZ4F2e2WmIHL5JI5m[3Kxc4TheIlvNTF? M1jTTlI2ODN5OEWx
U266  M{HjPGFxd3C2b4Ppd{BCe3OjeR?= MkDpNVAx|ryP MXyxbC=> NGL4eYJx[XK2aXHscJkh[myxY3vzJINmdGxiZHXheIgh[2G3c3XkJIJ6KG6nY4Lvd5RifGmwLUG= NWTaR5VROjVyM{e4OVE>
H929  M2DxfGFxd3C2b4Ppd{BCe3OjeR?= MmjsNVAx|ryP NEnWV|EycA>? NYDKepo3eGG{dHnhcIx6KGKub3Prd{Bk\WyuIHTlZZRpKGOjdYPl[EBjgSCwZXPyc5N1[XSrbj2x Ml;6NlUxOzd6NUG=
MM.1S  MWnBdI9xfG:|aYOgRZN{[Xl? NF7yW3AyODEQvF2= MUCxbC=> MYrl[oZq[2mnboTsfUBxemW4ZX70d{B{d3KjZnXubYIucW6mdXPl[EBk\WyuIHTlZZRpKGOxbXLpcoUhf2m2aDDu[YNzd3O2YYTpck0y NGe1[pAzPTB|N{i1NS=>
C6 MnnKRZBweHSxc3nzJGF{e2G7 MXq1NO69VQ>? MXK0PIg> MmPKdJJmfmWwdIOgeIhmKGyxc4Ogc4Yh[2WubDD2bYFjcWyrdImgZ4F2e2WmIHL5JJBz\WewZX7vcI9v\Q>? NESyOZIzPTBzM{S3PS=>
AGS NUfjOZFrSXCxcITvd4l{KEG|c3H5 MVi1NO69VQ>? MVWyOIg> NULmTZhZ[WKxbHnzbJMh|rJvbHHwZYNpd26nLXnu[JVk\WRiY3XscEBl\WG2aDDhcoQhcW6qaXLpeIVlKGe{b4f0bC=> NGL2TpMzPTByOU[5PC=>
HeLa  M1vGUmFxd3C2b4Ppd{BCe3OjeR?= MWG0NO69VQ>? MVuyOIg> NI\I[4JqdmirYnn0d{B1cGViaX7jdoVie2WmIHHwc5B1d3OrczDpcoR2[2WmIHL5JJNqWk6IMUKx MWKyOFkzQDZ6NR?=
THP-1  MljzRZBweHSxc3nzJGF{e2G7 NWjid41SOTEQvF2= NUfWd5ZTOWh? NFm0O4Vz\WS3Y3XzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KEGOQT3TSHTDqA>? MoS2NlQ6OjN4NUO=
P815  NX;sZXY5SXCxcITvd4l{KEG|c3H5 M1i4[VExOCEEtV2= Mn;SNVJp NG\F[GJFVVOR MlPJbY5pcWKrdIOgeolzfXNvaX7keYNm\CCjcH;weI9{cXN? NFrBfI8zPDl{M{K3Ny=>
HCT116 MoHhRZBweHSxc3nzJGF{e2G7 NXTzdmdVOjEQvF2= NHnMSYIzPGh? NYnqXW9H[WK{b3fheIV{KG:oIGTRMYlv\HWlZXSgZZBweHSxc3m= M2nlNFI1QDlyNES5
SW1116  M3XmO2Fxd3C2b4Ppd{BCe3OjeR?= MUCxNEDDvU1? NWHndnVSOWh? NULBeJFQTE2VTx?= MUXy[ZN1emGrboOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDn[YZqfGmwaXKgdIx2eyCmZXPpeIFjcW6n NHXPZo8zPDh5NEK4Oi=>
LOVO MmO3RZBweHSxc3nzJGF{e2G7 MnrpNVAhyrWP NVvaSVNLOWh? MUPEUXNQ NX7IOVdnemW|dILhbY5{KGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkh\2WoaYTpcoljKHCudYOg[IVkcXSjYnnu[S=> M1zV[VI1QDd2Mki2
SNU449  NHfWO49CeG:ydH;zbZMhSXO|YYm= MX[yNO69VQ>? MYi0PIg> MYPEUXNQ MoHm[IVkemWjc3XzJI1qWi12NUGtbY5lfWOnZDDhdI9xfG:2aXO= M{\RRVI1QDRzNkO4
Caco-2 NUTsUIJ6SXCxcITvd4l{KEG|c3H5 NXzYVWs3PDEkgJpOwG0> NH3pdHc1cA>? NIT2TZdxemW4ZX70d{BUXC15LXnu[JVk\WRiWl:tNUBkcGGwZ3XzJIFv\CCWRWKg[JJweA>? MVSyOFgzOjF6Mx?=
macrophage NYHYZ4lFS2WubDDWbYFjcWyrdImgRZN{[Xl? MU[wMVIxOM7:TR?= MnfPNlRp MmH2bY5lfWOnczDUUmYuKGGwZDDSbZA{NWSncHXu[IVvfCCwZXPyc5B1d3OrczDpckBu[WO{b4DoZYdm MVGyOFc6QTV4NR?=
AGS  M3HrfWFxd3C2b4Ppd{BCe3OjeR?= MUGyNO69VQ>? NYnYdm1COTKq MVLEUXNQ MlTXdoVlfWOnczD0bIUhcW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBz\XOyb37z[UB1dyC2aHWgSZRQSWNiZoLhZ5Rqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MYKyOFc5QTdyMx?=
LCC9  MYnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NXfOWZpZOTByzszN NWfKU|RtPWR? Ml3nZoxw[2u|IHPlcIwh\GWjdHigbY5lfWOnZDDifUBkd22kaX7heIlwdiCOMUegZY5lKGOqbH;yc5F2cW6n NV3JXlVkOjR5OEWyOVY>
U937  NXW0RYNqdmWlcn;weI9{cXNiQYPzZZk> NV30SmtLOTEEoN88US=> NEHGZ2c{OMLibXnu MYHpcoR2[2W|IH7lZ5JweHSxc3nzJINwdWKrbnWge4l1cCCWTl[= MkT1NlQ4PzN5NU[=
T cell NFTlT3RE\WyuIIDyc4xq\mW{YYTpc44h[XO|YYm= MVWwMVExOM7:TR?= M4Cy[FczcA>? NGXsS5hKSzVyPUewJO69VSxiaX7obYJqfHNiYX70bU1ETDNvaX7keYNm\CCWIHPlcIwheHKxbHnm[ZJifGmxbjDpckBRSk2Fcx?= MnfRNlQ4Pjh5MEe=
HeLa  MoDmRZBweHSxc3nzJGF{e2G7 M1;kVFUx|ryP M17LZ|czcA>? NGfWe|FFVVOR MYXwdoV3\W62czDhdI9xfG:|aYOgbY5lfWOnZDDifUBkd22yb4Xu[JPDqDIkgKO1 MVOyOFc2PDd6Nh?=
HeLa  M4m3VGFxd3C2b4Ppd{BCe3OjeR?= M1\tSFExOM7:TR?= NVj5eHhFOjSq NWTyO|Fme3WycILld5NmeyC{YYTlJI9nKGOnbHyg[IVifGhiaX7keYNm\CCkeTDveoVz\XiycnXzd4lwdiCxZjDHOVlUKG:{IFe3NXIheDF3MHfseYVlyqB? MmPBNlQ4OjJ2Nki=
IEC-6  MlLGRZBweHSxc3nzJGF{e2G7 NEfzU5MyOM7:TR?= NVK5[Gd6OjSq NEXnT4NxemW4ZX70d{BV[2SDLXnu[JVk\WRiY3HzdIF{\S1|IHPs[YF3[WenIHHu[EDPui2lYYTlcolvKGSnZ4Lh[IF1cW:w M3Trb|I1PzFzNUex
HCT116 MljwRZBweHSxc3nzJGF{e2G7 MXmyNO69VQ>? NWHRSVFYOjSq NUX0Z3p{cW6qaXLpeJMhfGinIHPlcIwh[XCxcITveIlkKGmwZIXj[YQh[nliWVzUNlA2 Mki3NlQ4OTN6MUK=
L02 MoXmRZBweHSxc3nzJGF{e2G7 MW[yNO69VQ>? M1qwS|Fp MlfsdJJmfmWwdIOgeIhmKGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkhVUWKUB?= NYHjPY5SOjR5ME[0OlE>
A375 M4Lte2Fxd3C2b4Ppd{BCe3OjeR?= NYPBRYhrOjEQvF2= NX\z[ohDOjSq MUfy[ZZmenOnczDkbYNqfHKrbn;u[UBDNWmwZIXj[YQh[XCxcITvd4l{ NELUZYIzPDZ7OUGxNS=>
HDPC NGnrVXVCeG:ydH;zbZMhSXO|YYm= MlvaOVDDvU1? NYPSfJI6OjSq Mm\ObY5pcWKrdIOgUm8ucW6mdXPl[EBieG:ydH;zbZM> MYSyOFY{PDV7Mx?=
A549 MlXLRZBweHSxc3nzJGF{e2G7 MXy1NOK2VQ>? MkjmNog> NFzodnRFVVOR M4S5NZBz\X[nboTzJJRp\SCqeYDv[IlxdG:rZDDEUmEh[2:wdHXueEBxcGG|ZTDpcoR2[2WmIHL5JINmeGijbH;jbJJwdWmw NF7xUJAzPDV6OEGzOS=>
 BV-2 MlXPRZBweHSxc3nzJGF{e2G7 NW[3fpZXOjEQvF2= MmL5Nog> NGDxW2t{fXCycnXzd4V{KFWYLXnu[JVk\WRiY3jyc41ifGmwIHX4eJJ2e2mxbjDhcoQh\GmuYYTpc44hd2ZidHjlJI52[2ynYYKg[Y53\WyxcHW= NWTE[446OjR3NUixNVg>
HT-29  MVTBdI9xfG:|aYOgRZN{[Xl? NU\Bc|NMPTEQvF2= Mo\tOFhp MWricI9kc3NidHjlJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGujZX3w[oVzd2x? MUKyOFU1QTF5NR?=
A549 NF7BUGVCeG:ydH;zbZMhSXO|YYm= M3fWR|XPxE1? NHfnfYMzPGh? NF\iVlF{fXCycnXzd4V{KD[nwrCoRmsyODB2MDmtbY5lfWOnZDDhdI9xfG:|aYRCpC=> NVr5[XhGOjR3Mkm4O|E>
MIA-PaCa-2 M3juPWFxd3C2b4Ppd{BCe3OjeR?= MkG4NlRp MWPicI9kc3NiY3zlZZZi\2Vib3[gZ4F{eGG|ZT2zJIlv\HWlZXSgZpkh[m:2aDDBMVQ1OzZ3NDDhcoQheGGlbHn0ZZhmdA>? NEniW|IzPDVzMEm5Ni=>
Caki-1 NFzhc29CeG:ydH;zbZMhSXO|YYm= M3rxXFIx|ryP MWixbC=> MVLpcohq[mm2czDTR3AucW6mdXPl[EBieG:ydH;zbZM> NUPpVY1xOjR3MES2PFE>
CLL NGDqenRCeG:ydH;zbZMhSXO|YYm= Mn7vNlXPxE1? NV7r[5R{OWh? MnPvdIFzfGmjbHz5JIJtd2OtczDNUG4zOjN6LXnu[JVk\WRiY3XscEBieG:ydH;zbZM> MlnxNlQ1Pjd4M{S=
SGC-7901 MVnBdI9xfG:|aYOgRZN{[Xl? NFn4RZQyOM7:TR?= NEHObYczPGh? NEXH[pZxem:vb4Tld{B1cGViQ1fJTU1qdmirYnn0[YQh[2WubDDndo94fGhiaX6gV2dENTd7MEGgZ4VtdHN? MkLVNlQ1PTR2OEi=
k1735 NX3odJZQSXCxcITvd4l{KEG|c3H5 M{fKTVIx6oDLzszt MUe0bC=> MkTqbY5pcWKrdIRCpHNidG2xbnXscIEucW6mdXPl[EBieG:ydH;zbZM> NXH3cVZxOjR2NUGxNVY>
HaCaT  MV\BdI9xfG:|aYOgRZN{[Xl? NE\2e4QyODEQvF2= MXqxbC=> NXW0VWdN[my3boTzJHVXSi2rbnT1Z4VlKGGyb4D0c5NqeyCrbjDIZWNiXCClZXzsdy=> NH\TbVUzPDN3Nkm5Oy=>
podocytes MXrBdI9xfG:|aYOgRZN{[Xl? M{TJO|IxOM7:TR?= NV[zNHRKPmh? NIf0SoVqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSB|LEStSGdG MXmyOFM{Pzd5Nx?=
 KB NIG3PZVCeG:ydH;zbZMhSXO|YYm= M{X5VVUx|ryP NHexRmMzPGh? NGnJOm9qdmirYnn0d{BNcWOxLVGtbY5lfWOnZDDjZZNx[XOnLUOgZY5lKFCDUmCgZYN1cX[jdHnvci=> M2rHc|I1OzN5NEmy
 HepG2  MmGwRZBweHSxc3nzJGF{e2G7 MV:xNO69VQ>? NHTRd|MzPGh? M1P6bZJm\HWlZYOgeolu\W62aX6gZ4xm[X[jZ3WgZ4F2e2WmIHL5JGxRWw>? NXXRZWc3OjR|MkW4NVY>
fetal rat lung fibroblasts  M3v4SmtqdmG|ZTDBd5NigQ>? M2fOZ|gx|ryPwrC= NH3aTpcycA>? NHThXHBqdmirYnn0d{BE[XOyYYPlMVMh[WO2aY\peJnDqA>? NGTqXVIzPDNzNEGzOS=>
PDL fibroblasts NH\J[oFMcW6jc3WgRZN{[Xl? MYW4NO69VcLi MYWxbC=> MVTpcohq[mm2czDDZZNx[XOnLUOgZYN1cX[rdIpCpC=> MmnDNlQ{OTRzM{W=
MB49 M4H3RmFxd3C2b4Ppd{BCe3OjeR?= Mn;ZNlDPxE1? NVvnVW8xOWh? MoS5doV3\XK|ZYOgR20ucW6mdXPl[EBk\WyuIHTlZZRp MVeyOFI5OjR|Mx?=
5637 M3vGTmFxd3C2b4Ppd{BCe3OjeR?= NIXWOVEzOM7:TR?= MmXBNYg> M4j4fZJmfmW{c3XzJGNONWmwZIXj[YQh[2WubDDk[YF1cA>? M2ntVVI1Ojh{NEOz
A549  MY\BdI9xfG:|aYOgRZN{[Xl? NH3yPFUyODEQvF2= NXjiZWZvPDiq M13mcpN2eHC{ZYPz[ZMhfGinIHHwc5B1d3OrczDjZZV{\WRiYomgdIlx\XKrbnZCpC=> M4rycVI1Ojd{MkCx
MCC-2 NUXLd2Y1SXCxcITvd4l{KEG|c3H5 M{LoOVIxKM7:TR?= MUO2bC=> M1XKNmROW09? NGnCfYxjdG:la4OgbY5lfWOnZDDifUB{fGG3cn;zdI9zcW6nIHHwc5B1d3OrczDj[YxtKGSnYYTo MUSyOFI3OjZ3OB?=
ADF MkC0RZBweHSxc3nzJGF{e2G7 M3v6OFQx|ryP MYK2bC=> M4\ZN4lvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGOqZX3veIhmemGyeTDwcJV{KFqwQ3yy NUPLbWY4OjR{MkiyN|I>
 U373  MWLBdI9xfG:|aYOgRZN{[Xl? M1m5RlQx|ryP MUe2bC=> MmjDbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkh[2inbX;0bIVz[XC7IIDseZMhYm6FbEK= MlrJNlQzOjh{M{K=
RKO-HIPK2i M{jCdmFxd3C2b4Ppd{BCe3OjeR?= NFvBOGI1OM7:TR?= MXe2bC=> Mmq4bY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkh[2inbX;0bIVz[XC7IIDseZMhYm6FbEK= M3jafFI1OjJ6MkOy
HEC-1B M2Hud2Fxd3C2b4Ppd{BCe3OjeR?= NWW4[ItEOjEQvF2= NVniXoR4OWh? NV\Dd4ozemWmdXPld{BVWC2rbnT1Z4VlKGGyb4D0c5Nqe8LiY3HzdIF{\S1|IHHu[EBk[XOyYYPlMVk> MljuNlQzOTN|NUi=
4T1 M{HvSWNmdGxiVnnhZoltcXS7IFHzd4F6 MYmyMlUuOTEQvF2= MmL4OIg> M3LTfGROW09? Mo\NdoV{[3WnczD0bIUh[3m2b4TvfIlkcXS7IH;mJFRVOSClZXzsd{BqdmS3Y3XkJIJ6KFOSRGSgbY4h[SClb37j[Y51emG2aX;uJIRmeGWwZHXueEBu[W6wZYK= M1fhbFI1OjB4MU[x
OS  MlLtRZBweHSxc3nzJGF{e2G7 MmjUNlDPxE1? MkXvOIg> NX61fpdbcW6qaXLpeJMhfGinIHPlcIwh\GWjdHigZ4F2e2WmIHL5JHBFXA>? MXeyOFIxPDl|Nx?=
RPE M3;ROGFxd3C2b4Ppd{BCe3OjeR?= MlTwNVAx|ryP NV;0OZp4PDiq NWK1[GR2eGG{dHnhcIx6KGmwaHnibZR{KHSqZTDjZYxx[WmwLUGgZY5lKC1{IHHjeIl3[XSrb36gZZMhf2WubDDhd{B1cGViY3HzdIF{\SCjY4TpeoF1cW:w Ml34NlQzODJyNUK=
UD29a NGTkXotCeG:ydH;zbZMhSXO|YYm= M4LURlUx|ryP NV7VWoFIOjSq NV3VXJJtcW6qaXLpeJMhfGinIHPlcIwh\GWjdHigZ4F2e2WmIHL5JG5WXDN? NWn0OJppOjRzOUC1O|Q>
SH-SY5Y  NGHXU4FCeG:ydH;zbZMhSXO|YYm= Mn:1NVDPxE1? M4L5WFI1cA>? MkmwZZR1\W63YYTld{Bk[XOyYYPlJIFkfGm4YYTpc44h[W6mIHPlcIwh\GWjdHigbY5lfWOnZDDifUBJVkVvMlTH MUiyOFE1PTR4Mx?=
HeLa  MYXBdI9xfG:|aYOgRZN{[Xl? NWPWOpZCOTBxMkFOwG0> NVP1SGlrOjSq NIrGe3lqdmirYnn0d{B1cGViYXP0bZZqfHlib3[geIhmKG2jan;ybZR6KG:oIITo[UBu\W2kZYLzJI9nKHSqZTDjZZNx[XOnLX\hcYltgQ>? MoXINlQyOzd{Nk[=
SCCVII  MlvHRZBweHSxc3nzJGF{e2G7 NUXBOlBlOjYQvF2= MYSxbC=> NGHUOGRqdmirYnn0d{B1cGViY3XscEBscWyuaX7nJIFnfGW{IHThd4F1cW6rYh?= M1HKPFI1OTJ4NE[0
RAW 264.7 MVfBdI9xfG:|aYOgRZN{[Xl? MkDvNlDPxE1? MVOxPIg> NVjiSZVMcW6lcnXhd4V{KEyFMz3JTU/Pui2jY4TpckBz[XSrbzDjc41x[XKnZDD0c{BGS1SYLV3PV{B1emWjdH3lcpQhd26ueR?= MnzpNlQyOTZ5MEe=
A549  MlLjRZBweHSxc3nzJGF{e2G7 NFrjXJozNjYQvF2= NVS2ZZliOjSq MlLX[IVkemWjc3XzJI9zcWSxbnnuMYlv\HWlZXSgZZV1d3CqYXf5JIF{KHenbHygZY5lKEyxc4Ogc4Yh|pURiH2gZYx{dyCxY3P1dpJm\CCmdYLpcoch[XW2b4DoZYdq[yCycn;j[ZN{ Mke0NlQyODJ3MkK=
UM-SCC-10A  NIqxTVZCeG:ydH;zbZMhSXO|YYm= MorUOVDDvU1? Mn7INog> MXry[YR2[2W|IHHwc5B1d3OrczDpcoR2[2WmIHL5JIhq\2hvZH;z[UBqe2:jbHHueI9t[WO2b37l NUfGOXJbOjRyOUi3OVM>
BGC-823 NUPpcG1GSXCxcITvd4l{KEG|c3H5 MnvYNVAh|ryP NF7FcZUzPGh? NY\Jb|VZemWmdXPld{B1\XS{YX7kdolv\S2rbnT1Z4VlKGGyb4D0c5Nqe8Li NY\USVF[OjRyOUi1NVE>
Nalm-6  MnrIRZBweHSxc3nzJGF{e2G7 M4HEcVIx|ryP NH7ve4s1cA>? MUHpcohq[mm2czDjZZNx[XOnLUigZY5lKGOjc4Dhd4UuOyCjY4TpeoF1cW:wIHHu[EBRSVKSLUGgZ4xm[X[jZ3W= NHrScoIzPDB|OUm2Oy=>
KHOS  MWrBdI9xfG:|aYOgRZN{[Xl? M3i0SVQx|ryP NFjrNXczPGh? M2XUTYJtd2OtczD0bIUhcW6lcnXhd4VlKGOuZXH2ZYdmKG:oIHPhd5Bie2VvMzDhcoQhWEGUUDDpcoR2[2WmIHL5JGJDVUR|wrC= NIj0V5czPDB{NUO2NS=>
G292 NYX0UWluSXCxcITvd4l{KEG|c3H5 M1PQcVQx|ryP NGLuT3QzPGh? M{njdIJtd2OtczD0bIUhcW6lcnXhd4VlKGOuZXH2ZYdmKG:oIHPhd5Bie2VvMzDhcoQhWEGUUDDpcoR2[2WmIHL5JGJDVUR|wrC= MXSyOFAzPTN4MR?=
MG-63 MWDBdI9xfG:|aYOgRZN{[Xl? MWm0NO69VQ>? NVHMXYwxOjSq MV3icI9kc3NidHjlJIlv[3KnYYPl[EBkdGWjdnHn[UBw\iClYYPwZZNmNTNiYX7kJHBCWlBiaX7keYNm\CCkeTDCRm1FO8Li NV3Pc5BROjRyMkWzOlE>
EBV-transformed B cells NUDwWI46SXCxcITvd4l{KEG|c3H5 NEfrblAzOM7:TR?= MkPvNog> MWrEUXNQ MUficI9kc3NiYX70bU1ETDhyIHHu[EBidnSrLVPEPFYh[W62aXLv[JkucW6mdXPl[EBieG:ydH;zbZM> NYG5U5hVOjRyMEi2Nlg>
IM-9 B MnrERZBweHSxc3nzJGF{e2G7 MYmyNO69VQ>? NFu1SWczcA>? NFL4NWlFVVOR NGLqco9jdG:la4OgZY51cS2FREiwJIFv\CCjboTpMWNFQDZiYX70bYJw\HlvaX7keYNm\CCjcH;weI9{cXN? NE\BfI4zPDByOE[yPC=>
CNE1 MXrBdI9xfG:|aYOgRZN{[Xl? NIPi[pIzOM7:TR?= MmDIOFhp NF[0N|hjdG:la4OgUGsuSS2rbnT1Z4VlKGGyb4D0c5Nqew>? NUT2Olh4OjN7OEWwNlk>
CNE2 M4TR[GFxd3C2b4Ppd{BCe3OjeR?= MoPuNlDPxE1? Mo\jOFhp NVzBdYFp[myxY3vzJGxMNUFvaX7keYNm\CCjcH;weI9{cXN? MnyxNlM6QDVyMkm=
HL-60 MojDRZBweHSxc3nzJGF{e2G7 M{LKb|UxyrWP MmPzNYg> MVLEUXNQ MoDobY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhSkFzNEW= MkLwNlM6PDh5NUG=
L929 MknnRZBweHSxc3nzJGF{e2G7 NF;aUmEyNjJ34pETOeKh|ryPwrC= NYL3S4d{OjSq M4PLe4F2\22nboTzJHRPTs7zLXnu[JVk\WRibnXjdo9xfG:|aYOgZY5lKGG3dH;wbIFogQ>? NYjHc|FEOjN7NEG3Olk>
Jurkat MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MXSy{txO MlPDOIg> M4LmcZJmfmW{c3XzJIdzd3e2aDDpcohq[mm2aX;uJIFv\CEQsj3jZZRmdmmwIHTlZ5Jm[XOnIHL5JGhUNUGVQR?= M4\3[lI{QDl4ME[x
RAW264.7  NIfFb|BCeG:ydH;zbZMhSXO|YYm= MUCxNEDPxE1? NVj3cpk4OjSq M4LDTIRm[3KnYYPld{B1cGViYYDvdJRwe2m|IHnu[JVk\WRiYomgS2E> MkTUNlM5OjB{MEO=
A431  MmLmT4lv[XOnIFHzd4F6 MUK0NO69VQ>? Ml3hNog> NVf0cFhC[myxY3vzJIZqe2W2aX6tbY5lfWOnZDDjcIVifmGpZTDv[kBk[XOyYYPld{BidmRiUFHSVC=> NUDWbGZUOjN6MECwOVg>
Jurkat M1zBdmNmdGxiVnnhZoltcXS7IFHzd4F6 NYLmNZFGOjVvMUCw{txO MW[2bC=> NIDYcllqdmirYnn0d{B7NU[DLVPNT{1qdmS3Y3XkJINmdGxiZHXheIg> M1rYbFI{QTN|NUOy
COS-7  NGn1NXpHfW6ldHnvckBCe3OjeR?= NVvQW2k5PTEEtV2= M{W5WlI1cA>? NF74doZi\m[nY4TzJJRp\SCycn;j[ZN{cW6pIH;mJGFVVjG|IIfpeIgheG:ueWGgeJJi[3S| MXSyN|k{OzJyOB?=
CAL27 NFSze4tCeG:ydH;zbZMhSXO|YYm= M13sZVExKM7:TR?= MlWyNog> M1fJcpN2eHC{ZYPz[ZMhS3W{LV7Qd{1z\WS3Y3XkJJZq[WKrbHn0fUBjgSC3cDD0c{A6OCV? M4X0SVI{QTF5M{m2
THP-1  NY\UdGEySXCxcITvd4l{KEG|c3H5 NInOTFgyOC13MN88US=> Mn7PNog> M3nz[olvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KHS{aYD0c4xq\GV? Mo\aNlM6ODB{OUm=
K562 NX3MUXFkSXCxcITvd4l{KEG|c3H5 M3rSPVIx|ryP MmfwOFhp M1:4[YlvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KDRvTWW= M{DTT|I{QDd4OEK2
HL-60 MV7BdI9xfG:|aYOgRZN{[Xl? MnPDNVAx|ryP NV;yOG5xOjSq NHLNT5FqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSCjYnnleIFv\SCmaYTldpBmdmW|wrC= M{KwbFI{QDZ3N{e4
HeLa  MkLiRZBweHSxc3nzJGF{e2G7 M{n0[VIx|ryP MojoNog> MonHbY5pcWKrdIOgSG1OWCCrbnT1Z4VlKGGyb4D0c5Nqew>? NFTabFEzOzh4M{m2Oi=>
U251 MkTkRZBweHSxc3nzJGF{e2G7 MViyNO69VQ>? Mlq5NlRp NIPUNoxqdmirYnn0d{Bk[XO2aXPpckBqdmS3Y3XkJGczN01icHjhd4Uh[XK{ZYP0JIFv\CCjcH;weI9{cXN? MlzDNlM5OTZ6MU[=
HL-60 NYn4W4tSSXCxcITvd4l{KEG|c3H5 MX21NOK2VQ>? MlzKOIg> MXzicI9kc3NidHjlJINt\WG4YXflJI9nKGOjc4Dhd4UuOyxiLUmsJIFv\CCSQWLQJIlv\HWlZXSgZpkhPnN? NVXVZ5dPOjN6MES3NFY>
Ec-109 M{CycGFxd3C2b4Ppd{BCe3OjeR?= Mm\nNVAh|ryP NH3RT|g1QGh? M1j6eJJmeHKnc4Pld{BRTS2vZXTpZZRm\CCHYz2xNFkh[2WubDDhdI9xfG:|aYO= NI\rTHYzOzd6Mk[0NS=>
RKO MnLCR4VtdCCYaXHibYxqfHliQYPzZZk> MUCxNEDPxE1? MnS0NlRp MWjpcohq[mm2czD0bIUh\GWlcnXhd4Uhd2ZiY3XscEB3cWGkaXzpeJkh[2G3c3XkJIJ6KESDQh?= M1;VRlI{PzV6ME[0
T98G MULD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1nSXlEuOTByzszN NULCZVNUOjSq NF;0NmtqdXC{b4\ld{Bk\WyuII\pZYJqdGm2eTDjc5Rz\WG2bXXueEB4cXSqIGTT MXSyN|c3QTJ5NR?=
Jurkat NVfqd5NIS2WubDDWbYFjcWyrdImgRZN{[Xl? NEjhcW8yODBvMkCw{txO NGHVPXYzPGh? MVXpcohq[mm2czDIZWE1KGmwZIXj[ZMh[XCxcITvd4l{KGSncHXu[IVvfCCxZjDjc45k\W62cnH0bY9vyqB? NXT4WWlwOjN5M{K0PFE>
Molt-3  M2DzNmFxd3C2b4Ppd{BCe3OjeR?= MonUOVDPxE1? MUCybC=> Ml7IdoVlfWOnczDt[YxifG:waX6tbY5lfWOnZDDhdI9xfG:|aYO= MY[yN|czPTBzMx?=
hMSC12 M{joWWFxd3C2b4Ppd{BCe3OjeR?= MUWxNFDPxE1? M4XMZ|Rl NV\oTI9[cW6qaXLpeJMhd3O2ZX;n[Y5q[yCldXz0eZJmNWmwZIXj[YQh[2WubDDk[YF1cCCjbnSgZ4Ft[2moaXPheIlwdg>? MYqyN|Y2Pzh{Mh?=
HM7  NE\Yd|BCeG:ydH;zbZMhSXO|YYm= NXzy[3JbOjEQvF5CpC=> MojKNYg> M4DKUYJtd2OtczDhdIlkfWyjcnXuJGEh[WOndHH0[U1qdmS3Y3XkJINie3Cjc3WtN{Bi[3SrdnH0bY9vKGGwZDDQRXJRKGOuZXH2ZYdm MkHmNlM2QDN2MUK=
Hep-2  NX64SnhmSXCxcITvd4l{KEG|c3H5 NETOR3UzOM7:TdMg M3H4UlI1cA>? NXu0cIVzTE2VTx?= M4LEWYFtdGW4aXH0[ZMhfGinIHTlZ5Jm[XOnIH;mJINmdGxidnnhZoltcXS7IHnu[JVk\WRiYomgd4ltcWKrbnnu NVGyd2RuOjN3OECwN|I>
HSCs NWrNb3lqSXCxcITvd4l{KEG|c3H5 M{HtflUx|ryP MkHBNlRp NVHL[ZZLTE2VTx?= NVLifpBocW6qaXLpeJMhdmmub4TpcoljNWmwZIXj[YQhTE6DIHThcYFo\SCrbnTpZ4F1\WRiYomgVGFTWCClbHXheoFo\Q>? M3f5bVI{PDl7OEe0
HL-60  NWPM[IhRS3m2b4TvfIlkcXS7IFHzd4F6 MWGyNO69VcLi M37SOVI1cA>? NYfSeWh5emWmdXPld{B1cGViY4n0c5RwgGmlIHXm[oVkfCCxZjDFdpk2 MnnlNlM1QTR2OEC=
HA MVXBdI9xfG:|aYOgRZN{[Xl? NYTYfnNFPTEQvF2= MoO0NlRp NHzJ[Zd{fXCycnXzd4V{KHSqZTDjcIVifmGpZTDv[kBRSVKSIHHu[EBk[XOyYYPlMVMtKC15LDDhcoQhNTliaX7keYNm\CCkeTDic5J1\XqxbXniM3NCUEF? Mmj5NlM1PzV7NU[=
C666-1 NVG3fGF2SXCxcITvd4l{KEG|c3H5 NXHUPY91PTEQvF2= NEnRW5AzPGh? MUXzeZBxemW|c3XzJJRp\SClbHXheoFo\SCxZjDQRXJRKGGwZDDjZZNx[XOnLUOsJE04NCCjbnSgMVkhcW6mdXPl[EBjgSCkb4L0[ZpwdWmkL2PBTGE> NX22[HRGOjN2N{W5OVY>
Hepa1-6 NUTIeIZ4SXCxcITvd4l{KEG|c3H5 MlXJOVDPxE1? NGnxdXAzcA>? NVnm[4Q{cW6qaXLpeJMh[3W{Y4XtbY4h[W6mIILld5ZmemG2cn;sMYlv\HWlZXSgZZBweHSxc3nz MnzDNlM1PDZ5NUO=
PLC/PRF/5c NVnRNVlGSXCxcITvd4l{KEG|c3H5 NXPxZlB1PTEQvF2= MVqxbC=> NHvVPVFxemW4ZX70d{BieG:ydH;zbZMhfHKrZ3fldoVlKGK7IFPJUi=> M4HHTlI{PDN6OEK0
HCT116 NX7SVlEzSXCxcITvd4l{KEG|c3H5 NXHqV4h{OTByzszN M17Jb|EvPWh? MoXCbY5pcWKrdIOgU5MucW6mdXPl[EBk\WyuIHTlZZRp MUKyN|c1PDN3Mx?=
HCEC M4[0dWZ2dmO2aX;uJGF{e2G7 NUK1U3c4PTEQvF2= MVW3Nog> MkXnSG1UVw>? MW\y[ZN1d3KnczDv[kB1cGVibn;ycYFtKEiFRVOgdIhmdm:2eYDl MmXQNlM4PDJyMUG=
Primary rat cerebral cortical neurons NUfFfIM6SXCxcITvd4l{KEG|c3H5 MWWxNFDPxE1? MYexbC=> NVH1XGpJeHKndnXueJMhS2RvaX7keYNm\CCjcH;weI9{cXNiYX7kJINmdGxiZHXheIg> M1;oXlI{PzRzM{G3
MDA-MB-231  NFL1UGNCeG:ydH;zbZMhSXO|YYm= NEWwOIszPc7:TR?= MnvtNlRp M3zQVYFjem:pYYTld{BkgXSxdH;4bYNqfHliYX7kJINt\WG4YXflJI9nKGOjc4Dhd4UuOyCjbnSgVGFTWCCrbnT1Z4VlKGK7IGLnNy=> M3XGNlI2OzN5NUS0
NLRP3-Tet-on-MC/9  NXzkcolKSXCxcITvd4l{KEG|c3H5 MmLtNVAuPDEQvF2= NUXQd|RKOTKq MoHGZZR1\W63YYTld{B1cGViY3XscEBl\WG2aDDjZZV{\WRiYomgR2FRWy2jc4PvZ4lifGWmIF7MVnA{KG23dHHueJMhcW5idHjlJHRmfC2xbjDzfZN1\W1? M2DVVFI{PzB|M{i5
KNS42  NVixO3ozSXCxcITvd4l{KEG|c3H5 NXTtO29QPTEQvF2= NHy5elUycA>? NUmzVGQ{emWmdXPld{Bk\WyuIHTlZZRpKGGwZDDjc41xdGW2ZXz5JIFjd2yrc3jl[EBk[XOyYYPlJFMwPyCjY4Tpeol1gSCrbjDy[ZNxd26|ZTD0c{BCSlRvMk[zM|JFTy:vZYTmc5JucW5iY3;tZolv[XSrb36= NVGwVWo2OjN4OUGxOFU>
MCF-7  NFHidFRCeG:ydH;zbZMhSXO|YYm= Mnu4NlDPxE4EoB?= MmnPO|Jp NVztdXBJcW6qaXLpeJMh\XG3b3ytJIFv\CB2LV;IWE1u\WSrYYTl[EBieG:ydH;zbZM> NGHtXGEzOzZ5NU[0Ny=>
hCMEC/D3  M2XyVmFxd3C2b4Ppd{BCe3OjeR?= M1[yb|I2|ryP M1rjVVczcA>? NH;hNVVz\WS3Y3XzJGx1gEFiaX7keYNm\CCjcH;weI9{cXN? MmG4NlM3PjVzOUi=
Jurkat NYX3ZYZISXCxcITvd4l{KEG|c3H5 MXKxNk42NTVyzszN NYOwVGhYOWh? MV;kc5NmKGSncHXu[IVvfGy7IIP1dJBz\XO|ZYOgV3BJNWmwZIXj[YQhWGG{LUSgZ4xm[X[jZ3WsJHBCWlBiY3zlZZZi\2VuIFTORUBnemGpbXXueIF1cW:wLDDhcoQhdG:|czDv[kB3cWGkaXzpeJk> MnW0NlM1PDJ7N{[=
CNE-1 M1jKO2Fxd3C2b4Ppd{BCe3OjeR?= M2HzOVIx|ryPwrC= MXqyOIg> MVTpcohq[mm2czDSRWQxODFvaX7keYNm\CClZXzsJIRm[XSq MkLjNlM1OjZ6NUC=
HONE-1 M4fVUGFxd3C2b4Ppd{BCe3OjeR?= M2jX[lIx|ryPwrC= NXrLd4M5OjSq MV;pcohq[mm2czDSRWQxODFvaX7keYNm\CClZXzsJIRm[XSq NFfiOHQzOzR{Nki1NC=>
astrocytes cell M3TETWFxd3C2b4Ppd{BCe3OjeR?= NILWVpQ1OM7:TR?= NW\TUIN[Pmh? NWfFcI5WemWmdXPld{Bm[XKueTDhdI9xfG:|aYOgbY5lfWOnZDDifUB{fGG3cn;zdI9zcW6n MViyN|QyOTd5OB?=
U-937 NG\5WGlCeG:ydH;zbZMhSXO|YYm= MlH5NVDPxE1? M{iwV|MxdWmw M{L6VJBz\X[nboTzJHRPTi2rbnT1Z4VlKG6nY4LvdJRwe2m| MV:yN|QyODd2OB?=
MDA-MB-231 NW\xT2FqSXCxcITvd4l{KEG|c3H5 NFTLeY4yODEQvF2= M17OW|Fp NXv2eHJpcW6qaXLpeJMhe2Wwc3n0bZpifGmxbjD0c{BVWkGLTDD1dI9vKE2WRFig[I94di2{ZXf1cIF1cW:w NYDSW2JuOjN2MEi0Nlk>
HeLa  Mn;IRZBweHSxc3nzJGF{e2G7 MUmxNFDPxE1? NFfpd4kzcA>? Mm\vZoxw[2u|IFrSV{0yPSCLbnT1Z4V{KEGyb4D0c5Rq[yCFZXzsJGRm[XSq NVnZNJBDOjN|NESwOFU>
Ec109 NXvhV2NGSXCxcITvd4l{KEG|c3H5 NVrNb4FGOTEQvF2= MV[2bC=> M{XaZYJtd2OtczDhdI9xfG:2aXOgZ49u[mmwYYTpc44hd2ZiVHH0MXNu[WOQNzDhcoQhemGmaXH0bY9v MVqyN|M{QDV4OB?=
H460  MWTBdI9xfG:|aYOgRZN{[Xl? M4PmZlEx|ryP NILORo83cA>? MYjicI9kc3NiYYDvdJRwfGmlIHPvcYJqdmG2aX;uJI9nKFSjdD3TcYFkVjdiYX7kJJJi\GmjdHnvci=> MWqyN|M{QDV4OB?=
HeLa  MYTBdI9xfG:|aYOgRZN{[Xl? M{nF[VUx|ryP Mkm4NU42cA>? NU[3fHh5[WK{b3fheIV{yqCFaHzhcZllcWFvaX7keYNm\CCjcH;weI9{cXN? MX2yN|MxOzhyNB?=
SK-HEP1 MmTJRZBweHSxc3nzJGF{e2G7 NVvSfm1HOTByzszN Mmq1NYg> MV7pcohq[mm2czDDdnQyKGGldHn2ZZRm\CClYYPwZZNmNTNuID23MEAuQCxiLUmsJIFv\CCyb3z5LGFFWC2{aXLvd4UqKHCxbInt[ZJie2V? NEWyfVkzOzNyMk[1NC=>
QGY7701 M4HneWFxd3C2b4Ppd{BCe3OjeR?= NX;SbXI{OjYQvF2= M2fOWlEvPWh? NV7lWIx6cW6qaXLpeJMh[WOldX31cIF1cW:wIH;mJJN2[i2JMTDwbIF{\SCrbnT1Z4VlKGK7IFTPXEAsKHG3ZYLj[ZRqdg>? NHLMN|MzOzJ2MEC2NS=>
HepG2 MnjTRZBweHSxc3nzJGF{e2G7 MWmyNO69VQ>? MlzIN|BucW5? MnLQbY5pcWKrdIOgeIhmKGWwaHHuZ4VlKGOnbHyg[IVifGhiYomgZ49u[mmwZXSgeJJm[XSvZX70JI9nKGGyaXflcolvKGGwZDDUVmFKVA>? NW\LTY1iOjN{MkSyN|k>
U87  NHq4[ldCeG:ydH;zbZMhSXO|YYm= NVnmbGxuOjYQvF2= NGntWXIzcA>? Mofv[IVkemWjc3XzJIl{d2yrcYXpdol1cWenbnnuJEhKW0xrLXnu[JVk\WRiYYDvdJRwfGmlIHPlcIwh\GWjdHisJIJ2fCCwb4SgcoVkem:2aXOgZ4VtdCCmZXH0bC=> Mm\SNlMzOjl4Mk[=
HSC-2 M{XmZmFxd3C2b4Ppd{BCe3OjeR?= M3PiTFI2NzVyzszN NYHsZ|ZLOWh? NYqzU204cW6qaXLpeJMhW05vM{itbY5lfWOnZDDjfZRwfG:6aXPpeJk> M3HwOlI{OTV3MkS4
HSC-4 NFnwV5ZCeG:ydH;zbZMhSXO|YYm= M{LjT|I2NzVyzszN NXTwXHBJOWh? NFfQfYtqdmirYnn0d{BUVi1|OD3pcoR2[2WmIHP5eI91d3irY3n0fS=> NIjaSHYzOzF3NUK0PC=>
CL-1 Ml2zRZBweHSxc3nzJGF{e2G7 MmL0NlDPxE1? NIXITnkycA>? NH\aVI9jdG:la4OgU3A1PDliaX7keYNm\CClZXzsJIRm[XSq MnGzNlMyOzF5OEK=
MEL NGHRXZdCeG:ydH;zbZMhSXO|YYm= NW\NUINJOjEQvF2= NX74dWdiOjSq NHz1Vm1FVVOR MVHpcZBicXKnczDQNng4NWmwZIXj[YQhVUWOIHPlcIwh[XCxcITvd4l{ M2W3fFI{ODF2OEi3
Bel-7402  MWLDZZNx[XOnIFHjeIl3[XSrb36gRZN{[Xl? MXW1NO69VQ>? MnrJNog> MX7pcohq[mm2czDQR2UucW6mdXPl[EBidm:ra3nz NYrPU48xOjNyMEi3OFI>
Eca-109 M3L5c2Fxd3C2b4Ppd{BCe3OjeR?= MnnXNlXPxE1? NF;ROlg{OG2rbh?= M3vpb4lvcGmkaYTzJGJLNUJzMT3pcoR2[2WmIHPlcIwh\GWjdHi= NWTaTY5TOjNyN{[5Olc>
MEL NInR[FRCeG:ydH;zbZMhSXO|YYm= NVfIenY6OjEQvF2= NYi4[W5IOWh? M3fXWGROW09? M{juNYlueGGrcnXzJHAzYDdvaX7keYNm\CCPRVygZ4VtdCCjcH;weI9{cXN? M2C4cVI{ODF2OEi3
Bel-7402  MoG0RZBweHSxc3nzJGF{e2G7 NWi1eHJnPTEQvF2= NV3TS401Omh? M4HWW4lvcGmkaYTzJHBETS2rbnT1Z4VlKGGwb3nrbZM> MknKNlMxODh5NEK=
L929 M3HzdmZ2dmO2aX;uJGF{e2G7 NFLjTJEzNjYQvF2= M1f2[lFp NV;M[pVUcW6lcnXhd4V{KFKLUEGg[ZhxemW|c3nvckBidmRiZYjhZ4Vz[mG2ZXSgWG5H|rFvaX7keYNm\CCvaYTvZ4hwdmS{aXHsJIR6e2[3bnP0bY9vKGGwZDDSU3MheHKxZIXjeIlwdg>? MoPHNlMxODB3MUi=
RCC  NYDT[lF6S2WubDDWbYFjcWyrdImgRZN{[Xl? MoPQNVAx|ryP NHnXdo8zPGh? NIDJbmtz\WOxdnXy[ZMhfGinII\pZYJqdGm2eTDv[kBk\WyuczDlfJBwe2WmIITvJFE2\C2SR1qy M1i4c|IzQTlzNEm0
NB2a/d1 NUT3V5pKSXCxcITvd4l{KEG|c3H5 MlLwNVAx|ryP NI\mOJc4Omh? NVjtWllw[XS2ZX71ZZRmeyC|dHH1do9{eG:{aX7lMYlv\HWlZXSgZ4F{eGG|ZTDhZ5Rqfmm2eTygVGFTWCxiYX7kJJRifSClbHXheoFo\Q>? NHTVNWEzOjl6OEW0NS=>
T cell M2HW[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjNb3RROjVvMUCw{txO NEXZZ4MzPGh? MkHV[I9{\S2mZYDlcoRmdnSueTDpcohq[mm2ZXSgWEBk\WyuIIDyc4xq\mW{YYTpc44hdWWmaXH0[YQhfGi{b4XnbEB1cGViY3:td5RqdXWuYYTpc44hf2m2aDDhcpRqNUOGMzDhcoQh[W62aT3DSFI5 MnXPNlI6QDJ3M{i=
K562 MWrBdI9xfG:|aYOgRZN{[Xl? MlO1NVAx|ryP M2XuSlFp NXz2SGpK[myxY3vzJGFjdm:kYY\pd4N2dcLiRj3pcoR2[2WmIHHwc5B1d3Orcx?= MXmyNlk4OjN5Mh?=
Jurkat  MVPBdI9xfG:|aYOgRZN{[Xl? NWq2ZWpzPDEQvF2= NGLzPXMycA>? NX\BXW1y[WKxbHnzbIV{KE[jc1ytbY5lfWOnZDDjZZNx[XOnIHHjeIl3[XSrb36gZY5lKGOnbHyg[IVifGh? M2DGXFIzQTR{N{O4
BGC-823 Mo\MRZBweHSxc3nzJGF{e2G7 MmTYNVAx|ryP NFvRRmMycA>? NHLLN4px[XK2aXHscJkhemW|Y4Xld{Bk\WyuczDh[4FqdnO2IHThcYFo\SCxZjDkZYllgmWrbh?= NEf6TXEzOjl{NkW0OS=>
Hep3B NEf4bZdCeG:ydH;zbZMhSXO|YYm= Mnu2OVDPxE1? NWHSbZZjOWh? NHvlOZNjdG:la4OgZZBweHSxc3nzJIlv\HWlZXSgZpkhUEWJQ4O= MWqyNlkzOzF3NB?=
LLC-PK1 NVf3d|BGSXCxcITvd4l{KEG|c3H5 M4rmN|Ix|ryP MVSxbC=> MUDwdoV3\W62czDjbZNxdGG2aX6tbY5lfWOnZDDk[Ydz[WSjdHnvckBw\iCDdHe1MEBj\WOuaX6tNUwh[W6mIFH0[|EzKHC{b4TlbY5{ MlzJNlI5QTZyM{e=
A549 MXHBdI9xfG:|aYOgRZN{[Xl? MoLGOVDPxE1? NH3wOIoycA>? M3mwWYJtd2OtczD0bIUhSkGLLXnu[JVk\WRiYYDvdJRwe2m|wrC= Ml\uNlI5QDd{MUW=
SGC-7901  MV;BdI9xfG:|aYOgRZN{[Xl? MkjjNVDPxE1? NIfNdGgzPGh? NE\ub5FqdmirYnn0d{DPui{Qsj3kbY1mfGi7bHHjdplte2ira3;ubY4ucW6mdXPl[EBieG:ydH;zbZPDqA>? NHr1N3QzOjh2OEW5Oy=>
DM6 Mkn2RZBweHSxc3nzJGF{e2G7 MWixNFDPxE1? NYniZlZqPzKq MWPicI9kc3NiYn;0bEBGOkZvMTDhcoQhTTKIdIKtcYVlcWG2ZXSgZ5l1d3SxeHnjbZR6 NWLMWIU6OjJ6MkWzNlg>
MCF-7, MDA-MB-468, Caco-2 NXK5V3FWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfs[I13PTEQvF2= MVS0PIg> M4XZ[4lvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpcohq[mm2aX;uJIlv\HWlZXSgZpkhe2Gyb37pci=> NFXiSpYzOjhyMEm2PC=>
A2750  MUPBdI9xfG:|aYOgRZN{[Xl? Mo\wNlDPxE1? NHzjRmMzcA>? M4DVZmROW09? NYOxWpZP[myxY3vzJINie3Cjc3WgZ4xm[X[jZ3Wg[JVzcW6pIHjlcIVv[WyrbjD0doVifG2nboSgZY5lKHKnZIXj[ZMh[XW2b4DoZYdq[yClZXzsJIRm[XSq MW[yNlc5PDN4Mx?=
U87  MX\BdI9xfG:|aYOgRZN{[Xl? NETUdGkzOM7:TR?= NYnF[3J[OjSq NYTo[pllemWmdXPld{B1cGViYYDvdJRwe2m|IILheIUhcW6mdXPl[EBjgSCSTFHC M2jwZlIzPzd6N{iw
HT1080 NFTuUllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33Ob|Ux|ryP NGXyb2Y4\A>? NXXHUot{cW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJIlvcGmkaYTpc44h[2G3c3XkJIJ6KGOxbXLpcoVlKHS{ZXH0cYVvfCCxZjDER2Eh[W6mIF;NVC=> MoL1NlI4PDB7OES=
A549  MVnBdI9xfG:|aYOgRZN{[Xl? NWjxTpR4PTEQvF2= NGrNUGozcA>? MkT4dIFzfGmjbHz5JIRm[3KnYYPld{B{d2SrdX2gd4Vt\W6rdHWtbY5lfWOnZDDhdI9xfG:|aYO= NVnpWJR5OjJ5MkG4NFQ>
Primary OPC NEjCUWVCeG:ydH;zbZMhSXO|YYm= MXmx{txO M3XO[|ZpNzJ2aB?= M3nZcJJm\HWlZYOgeIhmKHCncnPlcpRi\2Vib3[gZ4VtdHNiaX6g[YFzdHlvIHHu[EBt[XSnLXHwc5B1d3Orcz;u[YNzd3Orcx?= MUCyNlcxPzN6NR?=
PMNs NVLRVI5pSXCxcITvd4l{KEG|c3H5 M1z3V|Qx|ryP MWC2bC=> NILueINFVVOR NVjj[5ZuemW4ZYLz[YQhfGinIHHtc5VvfCCxZjDjcIVifmWmIHPhd5Bie2VvMzD0c{Bv\WG{II\lbIlkdGVibHX2[Yx{ MofKNlI3QTJ3N{e=
A549  M1ryOWFxd3C2b4Ppd{BCe3OjeR?= MV21NO69VQ>? NFzsO|EycA>? M4rqfZBz\X[nboTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KEKjb3j1c5Nq\GViSR?= NIPmTlkzOjZ6N{[zOS=>
AGS M3rIbWFxd3C2b4Ppd{BCe3OjeR?= MnH5NlDPxE1? MYOxNog> MXfpcohq[mm2czD0bIUh[WO2aY\heIlwdiCxZjDwdo8u[2G|cHHz[U0{KGmwIILld5BwdnOnIITvJJRp\SCHdF;BZ{BnemGldHnvci=> NIrVUnAzOjZ6N{O5PC=>
shC9  MkDvRZBweHSxc3nzJGF{e2G7 M2PlbFEx|ryP MoHmNVZp M3vCPIJtfW62czDTTGgh\XiycnXzd4lwdiCrbjDzbGM6KGOnbHzzJIV5eG:|ZXSgeI8h\Wm2aHXyJHBCKG:{IFzQRy=> MUeyNlY1OTB7NB?=
primary MEFs NIDO[lJHfW6ldHnvckBCe3OjeR?= M3n3TlEzcA>? NVvoPXhkyqCrbnPy[YF{\XNiZYTvdI9{cWSnLXnu[JVk\WRibXn0c4Npd26mcnnhcEBu\W2kcnHu[UBl\XCxbHHybZpifGmxbh?= NVniR4ZnOjJ4MUO3Olc>
3T9 MEFs NXTEWVNzTnWwY4Tpc44hSXO|YYm= NGOzPWIyPmh? MnPsbY5kemWjc3XzJIN6fG:laILvcYUh[yC{ZXzlZZNmKGGodHXyJIV1d3Cxc3nk[U11emWjdH3lcpQ> M1XoZlIzPjF|N{[3
3T9 MEFs NHezW|JHfW6ldHnvckBCe3OjeR?= MWGxPIg> M{PkOpVxemWpdXzheIV{KGmwaYTpZZRweiClYYPwZZNmNTliYoX0JIRwf26{ZXf1cIF1\XNiZX\m[YN1d3JiY3HzdIF{\XNiYX\0[ZIh\XSxcH;zbYRmKHS{ZXH0cYVvfA>? MlfUNlI3OTN5Nke=
MDA-MB-231  NG\oSG5CeG:ydH;zbZMhSXO|YYm= MY[yNO69VQ>? M3H3fFRl MWLy[YR2[2W|IITo[UBk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JI1mfG[xcn3pckB1emWjdH3lcpQhf2G|IIPp[45q\mmlYX70cJk> M2rDTFIzPTl|NESx
C6  MlLORZBweHSxc3nzJGF{e2G7 NWDCcIh3OTEQvF2= Mmn3NlRp Mnu1Zoxw[2u|IITo[UB{fXCycnXzd4l3\SCnZn\lZ5Qhd2ZidHjlJJBmeHSrZHWgc44hfmmjYnnsbZR6 MnjhNlI2QDh7OEC=
HL-60  MXHBdI9xfG:|aYOgRZN{[Xl? MXixNFDPxE1? M4TxW|I1cA>? M3fMXYlvcGmkaYTzJJRp\SClZXzsJIFxd3C2b4Ppd{B{\WynY4Tl[EApMylvbXXueIh6dCEQsj2oNgKHmjZrLXTp[4x2[2:yeYLhco9{cWSnwrC1 M4LIXFIzPTR4Nk[5
HL-60 NGXCNllCeG:ydH;zbZMhSXO|YYm= NE\4ZlUyOC16MN88US=> NX7abWpRPGh? MYHpcohq[mm2czDUS2hSNWmwZIXj[YQh[2WubDDhdI9xfG:|aYRCpC=> MlnRNlI2OjN{Mkm=
BCC NXq2V2V{SXCxcITvd4l{KEG|c3H5 NWrNSnpqPTEQvF2= NWPMcHA6OWh? MX7pcohq[mm2czDERXRUNW2nZHnheIVlKGe{b4f0bEBqdmirYnn0bY9v Ml;KNlI2OTl2M{[=
RAW 264.7 MYfBdI9xfG:|aYOgRZN{[Xl? M2TnbVUxNzFyMN88US=> M2XYXVFp NWjkZoZM[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5pcWKrdIOgSG9PNWmwZIXj[YQhelKQQTDjcIVifmGpZR?= NHT4[JUzOjR7MUSyOi=>
K562 MWDBdI9xfG:|aYOgRZN{[Xl? MWOyOe69VQ>? NV3mSnRROmh? NFXveZZxemW4ZX70d{BieG:ydH;zbZMhcW6mdXPl[EBjgSClbz30doVifG2nboSge4l1cCCjbYXy[Y5{cW5iRzDhcoQhXFKDSVy= NXT2OmdLOjJ2OEO3O|c>
SGC-7901 MXPBdI9xfG:|aYOgRZN{[Xl? NWLNUFQzOjBizszNxsA> MmnQNog> M1rZXYF1fGWwdXH0[ZMhUDKRMtMgc5IhXE6IIN8xMYlv\HWlZXSgZ4VtdCCjcH;weI9{cXNiYYOge4VtdCCjczDjZZNx[XOnLUOgZYN1cX[rdIpCpC=> Mo\hNlI1PzF3OEm=
PC3 MmLRRZBweHSxc3nzJGF{e2G7 MXGxNO69VQ>? MmnpOIg> NHrTOWlkd3WwdHXyd{BndGG4b3PvfIllNWmwZIXj[YQh[2G|cHHz[U1z\WyjdHXkJIFxd3C2b4Ppdy=> M2qzT|IzPDdzOUe0
SMMC-7721 NH63S|NCeG:ydH;zbZMhSXO|YYm= NFnwe3E2OM7:TR?= M3L1c|Q5cA>? MmfLZZR1\W63YYTld{BwXFJvaX7keYNm\CCjcH;weI9{cXN? M{jTWVIzPDZ3OEOz
HeLa  NEPEWnJCeG:ydH;zbZMhSXO|YYm= M1H5SVUxyqEQvF2= NVnObYdkPC96aB?= M4PHSolvcGmkaYTzJHNVWy2rbnT1Z4VlKGyjdHWtdIhie2ViYYDvdJRwfGmlIHX2[Y51ew>? M1q1dlIzPDZyNUC0
HeLa  NXnRd|JjSXCxcITvd4l{KEG|c3H5 NFLJeoY2OMLizszN MmnnNYg> MULzeZBxemW|c3XzJJRp\SCIUlHQMYlv\HWlZXSgZYNkfW23bHH0bY9vKG:oIHHucoV5cW5iVjDwc5NqfGm4ZTDj[Yxtew>? M3fwOlIzPDR7NESw
T47D  M2fZdmFxd3C2b4Ppd{BCe3OjeR?= M3vZd|ExOM7:TR?= NWfoO2hiOWh? MXHicI9kc3NidHjlJIdmdmW{YYTpc44hd2ZiRT3jZYQwS1SIMjDifUBUXFN? NWHObYExOjJ2MEGxOlg>
HeLa  MU\BdI9xfG:|aYOgRZN{[Xl? NYS2SWwzOzEQvF2= NVrVeGtzPGh? M{Py[uKhcW6lcnXhd4V{KHSqZTDn[Y5memGuIHPlcIwhfmmjYnnsbZR6KDR6IHigZYZ1\XJicHjveI9lgW6jbXnjJJRz\WG2bXXueOKh M4jSbFIzOzl2MkS4
HCC NIKyR|dCeG:ydH;zbZMhSXO|YYm= MkT1NlAh|ryPwrC= NYnJSop3Omh? MU\heJRmdnWjdHXzJJRp\SCGSFGgbY5lfWOnZDDhZ5RqfmG2aX;uJI9nKFCDUmC= Ml3aNlI{PDJ5M{K=
mESCs NWS3Z29MSXCxcITvd4l{KEG|c3H5 M3zEb|IvPc7:TR?= NYPIO3NlOmh? NEfiRlhqdmirYnn0d{B1cGViTnHGMY1m\GmjdHXkJINie3Cjc3WgZYN1cX[jdHnvci=> MlvvNlIzQDV{N{S=
EMT-6  MnqyR5l1d3SxeHnjbZR6KEG|c3H5 M1HKdlExOM7:TR?= MojaNYg> M3zXcpBienSrYXzsfUBjdG:la3XkJINmdGxiZHXheIghcW6mdXPl[EBjgSC|aYLhcYV{cW6n M1XJR|IzOjVzOUKx
MCF7 NVnKRocxSXCxcITvd4l{KEG|c3H5 NWD1[|ZuPTEEoN88US=> NHnocGoycA>? MV7pcohq[mm2czDQRUBi[3SrdnH0[YQh[2G|cHHz[U0{NCBvOTygZY5lKHCxbImoRWRRNXKrYn;z[UkheG:ueX3ldoF{\Q>? MYmyNlIzOzN2NR?=
K562 M4r0PGFxd3C2b4Ppd{BCe3OjeR?= NGT6UIMzOCEQvF5CpC=> MoLCOFhp MYrEUXNQ NG[4U2tjdG:la4OgcIFx[XSrbnniMYlv\HWlZXSgbY5pcWKrdHnvckBw\iC4aXHibYxqfHliYX7kJIFxd3C2b4Ppd{BqdmS3Y4Tpc44> MYCyNlIyPjF3OB?=
Molt4-hyg M3v4[WFxd3C2b4Ppd{BCe3OjeR?= NVHUSnV2OTEQvF2= M3;z[|AvPWh? M{LXVYJtd2OtczDmZZJv\XOxbD3pcoR2[2WmIHPhd5Bie2VvMz3sbYtmKGGldHn2bZR6 MkjFNlYzPzV6MUG=
HeLa MXnBdI9xfG:|aYOgRZN{[Xl? NGm2d3QyOM7:TR?= MmH2NE42cA>? MUPpcohq[mm2czDhdI9xfG:|aYOgbY5lfWOnZDDifUB1cGViY3;tZolv\WRidILlZZRu\W62IIfpeIgh\2:vaYPpckBPKGGwZDDUVmFKVA>? MWGyNlE4QTZ4MR?=
Jurkat T NXvoTXB1SXCxcITvd4l{KEG|c3H5 M2PFdlMx|ryP NF\lN|AxNjWq Mnr6SG1UVw>? MV7icI9kc3NidHjlJJpqemGvLXnu[JVk\WRiYYDvdJRwe2m| MUiyNlE2QTh7OB?=
Neutrophil MmfnRZBweHSxc3nzJGF{e2G7 NVqwSlhiOjEQvF2= M{LmW|AvPWh? NXTibVFJ[XS2ZX71ZZRmeyC2aHWgdJJwNWGyb4D0c5Rq[yCnZn\lZ5Qhd2ZiTXHSNS=> MUOyOlE6Pjh2NB?=
HCT116 M{\BSmFxd3C2b4Ppd{BCe3OjeR?= MmjNOVDDqM7:TR?= MnHINog> Ml\idoV3\XK|ZYOgd5lv\XKpaYP0bYMh[XCxcITvd4l{KGWoZnXjeJMhd2ZiY3Xs[YNwgGmkIHHu[EBPWENvMUdCpC=> NXTzPZhpOjJzNUm3OVI>
MDA-MB-231  NGfreWNCeG:ydH;zbZMhSXO|YYm= MXOyMlUuPy53zszN MkjJNog> M3W4SYlvcGmkaYTzJJRp\SClZXzsJIRm[XSqIH;mJG1FSS2PQj2yN|Eh[2WubIOgbY5lfWOnZDDifUBUTFRiaX6gZUBkd26lZX70doF1cW:wIHTldIVv\GWwdDDtZY5v\XJ? NYfFfmZXOjJzMUW1NlY>
LNCaP M4TqSWFxd3C2b4Ppd{BCe3OjeR?= M1\nb|Qx|ryP NIS5NIYzcA>? M2DzO4lvcGmkaYTzJIJ2fGWrbjDpcoR2[2WmIHPlcIwh[XCxcITvd4l{ NViwUoE3OjJzMUS3OlQ>
MB231 MVnBdI9xfG:|aYOgRZN{[Xl? M3;JVlExOM7:TR?= MlTQNYg> MXPEUXNQ MnrvZYJzd2ejdHXzJJRp\SCrbnT1Z5Rqd25ib3[gZ4VtdCCmZXH0bEBjgSCZRVWxJIlvcGmkaYTpc44tKFSUQVnMJJRz\WG2bXXueEwh[W6mIITo[UBkd22kaX7heIlwdg>? MV6yNlEyOjl2MB?=
HCC38  Mn3RRZBweHSxc3nzJGF{e2G7 NHzYZmYyODEQvF2= MWexbC=> M1nIdWROW09? M2e4O4Fjem:pYYTld{B1cGViaX7keYN1cW:wIH;mJINmdGxiZHXheIgh[nliV1XFNUBqdmirYnn0bY9vNCCWUlHJUEB1emWjdH3lcpQtKGGwZDD0bIUh[2:vYnnuZZRqd25? MVuyNlEyOjl2MB?=
MDA-MB231 NVj1XIxlSXCxcITvd4l{KEG|c3H5 NEnWOow2OMLizszN NVTISYxsOjSq MUPEUXNQ NFHDXWRi[nKxZ3H0[ZMh[3W{Y4XtbY4ucW6mdXPl[EBk\WyuIHTlZZRp M1P2ZVIzOTBzM{O1
LNCaP M3jLWGFxd3C2b4Ppd{BCe3OjeR?= MVm1NOKh|ryP NYX6NYRZOjSq MlnSSG1UVw>? M4r6UoFjem:pYYTld{BkfXKldX3pck1qdmS3Y3XkJINmdGxiZHXheIg> M1v1WlIzOTBzM{O1
HCT116 Mnz2RZBweHSxc3nzJGF{e2G7 MmHkOVDDqM7:TR?= MnH5NlRp NGjR[oJFVVOR MXLhZpJw\2G2ZYOgZ5Vz[3WvaX6tbY5lfWOnZDDj[YxtKGSnYYTo Mk\uNlIyODF|M{W=
Ishikawa  M17m[2Fxd3C2b4Ppd{BCe3OjeR?= NFnFfJYzPc7:TR?= NF\2U2ozPGh? NH3jNJRz\WS3Y3XzJINmdGxiZHXheIgh[W6mIHHwc5B1d3OrczDpcoR2[2WmIHL5JGJi\iCDMR?= M2TtbFIzODh6OUG4
 YD-8  NEnSc|BCeG:ydH;zbZMhSXO|YYm= MkK1NVAx|ryP NI\WdIkycA>? MVXpcohq[mm2czDQUGVQNWmwZIXj[YQh[XCxcITvd4l{ NUfoboRmOjJyOE[xPFM>
eosinophil  MkTwRZBweHSxc3nzJGF{e2G7 MXO5NO69VQ>? M2nDNVI1cA>? MW\pcohq[mm2czDhdI9xfG:|aYOgbY5lfWOnZDDifUBH[XNiYX70bYJw\HoEoB?= NUPNSm1iOjJyN{mzN|Q>
L929 MmrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7tU2g5Oi53zszN NFjzbpczPGh? NYfCWIxScW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4YheC2yM{igZY5lKE6ILd86RkB1dyCjdXft[Y51KFSQRt8xMYlv\HWlZXSgcoVkem:ydH;zbZMh[W6mIHH1eI9xcGGpeR?= MXSyNlAzPzB7Nx?=
YD-8  MVrBdI9xfG:|aYOgRZN{[Xl? NIW1VnYyODEQvF2= NIPIRmMycA>? M1LLb4Jtd2OtczD0bIUhT1NvSFPsMYlv\HWlZXSgZZBweHSxc3nz NEDzeYYzOjB{MEC3PC=>
HBx NUGxT5luSXCxcITvd4l{KEG|c3H5 NFnFUFMzPc7:TR?= MXG0PIg> NITBT2dFVVOR NEHpOIxz\WS3Y3XkJINmdGxiZHXheIghcW6mdXPl[EBjgSB|LV3B M3\qU|IzODJyMEe4
U937  NWrQcIM{SXCxcITvd4l{KEG|c3H5 MV[1NOKh|ryP NHzzSngycA>? M3TFe4lvcGmkaYTzJGhHNWmwZIXj[YQh[XCxcITvd4l{yqB? M4TLXFIyQTl6N{Ox
HL60 MknHRZBweHSxc3nzJGF{e2G7 NHjMbpc1OM7:TR?= NXu0eXNuPDCvaX6= MnX0SG1UVw>? NYT2[ZNE[myxY3vzJGJPTENiY3;tdI92dmS|IHnu[JVk\SCneIDvd5Vz\SCxZjDwbI9{eGijdHnkfYx{\XKrbnWgZY5lKESQQTDmdoFodWWwdHH0bY9v M1PkVVIyQTh|Mkm2
M-14 NVG2TGJRSXCxcITvd4l{KEG|c3H5 MnfVNlXPxE1? MVywMlVp MVtCpIlvcGmkaYTzJIJwfGhidHjlJINzfWSnIHX4eJJi[3RvIHHu[EBkd22yb4Xu[E1qdmS3Y3XkJIFxd3C2b4Ppdy=> NHLCcnEzOTl3NEm1PS=>
SK-BR-3 MYrBdI9xfG:|aYOgRZN{[Xl? MoLoOVDDqM7:TR?= MoC0Nog> M4LEe4Jtd2OtczDhdI9xfG:2aXOgSG5CKG[{YXft[Y51[XSrb36gbY5lfWOnZDDifUBkd22kaX7heIlwdiCxZjDTUU0yPjRiYX7kJJJi\GmjdHnvci=> MoLTNlE6ODF|OE[=
MDA-MB-468 MlLKRZBweHSxc3nzJGF{e2G7 MW[1NOKh|ryP MnnPNog> MkLxZoxw[2u|IHHwc5B1d3SrYzDEUmEh\nKjZ33lcpRifGmxbjDpcoR2[2WmIHL5JINwdWKrbnH0bY9vKG:oIGPNMVE3PCCjbnSgdoFlcWG2aX;u MWKyNVkxOTN6Nh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
IRF-1 / p-STAT1 / cleaved PARP1 / cleaved-caspase3; 

PubMed: 27191889     


With the addition of Z-VAD-FMK, levels of cleaved Caspase-3 and PARP1 were decreased.

Beclin1 / Atg5 / Atg7 / LC-3I / LC-3II; 

PubMed: 27191889     


Levels of Beclin1, Atg5, Atg7 and LC3-II were decreased after IFN-γ stimulation. However, when IFN-γ was combined with the caspase inhibitor, levels of Beclin1, Atg5, Atg7 and LC3-II were not decreased as determined by the Western Blot test. 

p23 / Hsp90 / hTRET / MMP2; 

PubMed: 19740745     


Expression of Hsp90 client proteins during cell death. HeLa cells were preincubated with z-VAD-fmk (100 μM) for 1 h and exposed to various concentrations of tunicamycin (Tu, in μM) for 24 h. Cell extracts were prepared and analyzed by Western blotting. β-Actin was used as the loading control.

cyto C; 

PubMed: 17301139     


z-VAD-fmk did not inhibit cytochrome c release in RRV-infected MA104 cells (RRV: rhesus rotavirus). Mock- and RRV-infected MA104 cells either were not pretreated or were pretreated with 100 μM z-VAD-fmk for 2 h before RRV infection, and treatment was continued during infection. Fourteen hours after RRV infection, the cytosolic and heavy-membrane fractions were assayed for cytochrome c by Western blotting. Mock-infected MA104 cells were used as negative controls. Cox IV and tubulin were used as protein loading controls for the heavy-membrane and cytosolic fractions, respectively. Positions of molecular weight markers are indicated on the left.

27191889 19740745 17301139
Growth inhibition assay
Cell viability; 

PubMed: 12522090     


Inhibition of magnolol-induced apoptotic cell death by z-VAD-fmk. CH27 cells were treated with cell permeable broad-spectrum caspase inhibitor (z-VAD-fmk) 2 h prior to 80 μm magnolol treatment. Cell viability was estimated. ***P<0.001, compared with the 80 μM magnolol-treated group. 

12522090
Immunofluorescence
cytochrome c ; 

PubMed: 11726499     


Immunolocalization of Smac/DIABLO and cytochrome c in HeLa cells. (A-C) Viable (non-apoptotic) HeLa cells were stained with antibodies to cytochrome c (green) and Smac/DIABLO (red) as indicated. Note that both proteins clearly co-localize within punctate, mitochondrial structures. (D–F) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were UV-irradiated followed by further incubation for 8 h. Note the cells where cytochrome c has exited mitochondria and can be seen in a diffuse pattern throughout the cell, including the nucleus (white arrows). In the latter case, note the retention of Smac/DIABLO in punctate mitochondrial structures within the cytoplasm. (G-I) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were then treated with 10 µM actinomycin D for 8 h. Once again note the retention of Smac/DIABLO in mitochondrial structures. (J-L) HeLa cells were treated as described in (G-I). A close-up of a single cell that has undergone mitochondrial cytochrome c release, but where Smac/DIABLO is retained within mitochondria, is shown.

Smac/DIABLO; 

PubMed: 11726499     


Immunolocalization of Smac/DIABLO and cytochrome c in HeLa cells. (A-C) Viable (non-apoptotic) HeLa cells were stained with antibodies to cytochrome c (green) and Smac/DIABLO (red) as indicated. Note that both proteins clearly co-localize within punctate, mitochondrial structures. (D–F) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were UV-irradiated followed by further incubation for 8 h. Note the cells where cytochrome c has exited mitochondria and can be seen in a diffuse pattern throughout the cell, including the nucleus (white arrows). In the latter case, note the retention of Smac/DIABLO in punctate mitochondrial structures within the cytoplasm. (G-I) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were then treated with 10 µM actinomycin D for 8 h. Once again note the retention of Smac/DIABLO in mitochondrial structures. (J-L) HeLa cells were treated as described in (G-I). A close-up of a single cell that has undergone mitochondrial cytochrome c release, but where Smac/DIABLO is retained within mitochondria, is shown.

Endo G; 

PubMed: 12941691     


GFP-Bax expression and immunostaining of EndoG together with nuclear Hoechst staining in HeLa cells 18 h after transient transfection with a vector encoding GFP-Bax in the absence or in the presence of the caspase inhibitor z-VAD-fmk (100 μM). 

AIF; 

PubMed: 12941691     


GFP-Bax expression and immunostaining of AIF together with nuclear Hoechst staining in HeLa cells 18 h after transient transfection with a vector encoding GFP-Bax in the absence or in the presence of the caspase inhibitor z-VAD-fmk (100 μM). 

11726499 12941691
ELISA
IL-1β; 

PubMed: 26254306     


Cell-free medium supernatants were harvested at 5 h. IL-1β levels were measured by ELISA. Z-VAD-FMK was used as a positive control. Bars represent means ± sem of pooled results from 3 experiments performed in triplicate at different times.

26254306
In vivo In vivo Z-VAD-FMK administration has been shown previously to be nontoxic and to prevent apoptosis in animal models. Intraperitoneal HK-GBS injection leads to preterm delivery, and pretreatment with Z-VAD-FMK delays preterm delivery in mice. In OVA-sensitized mice,treatment of z-VAD-fmk inhibits allergen-induced leukocyte infiltration. Systemic injection of the pan-caspase inhibitor z-VAD-fmk immediately before OVA challenge reduced inflammatory cell accumulation, mucus hypersecretion, and Th2 cytokine release in OVA-sensitized/challenged mice. Treatment with z-VAD-fmk blocked terminal differentiation of lens epithelial cells and keratinocytes, the differentiation of monocytes into macrophages, and the differentiation of erythroid progenitors. z-VAD-fmk attenuated allergen-induced airway inflammation and hyperreactivity. Treatment with z-VAD-fmk in vivo also prevented subsequent T cell activation ex vivo[7].

Protocol

Cell Research:

[6]

- Collapse
  • Cell lines: human granulosa cell lines (GC1a, HGL5, COV434)
  • Concentrations: 50 μM
  • Incubation Time: 48 h
  • Method:

    To validate the efficacy of Z-VAD-FMK, three human granulosa cell lines (GC1a, HGL5, COV434) were treated for 48 h with etoposide (50 μg/ml) and/or Z-VAD-FMK (50 μM) under normoxic conditions. To mimic the ischemic phase that occurs after ovarian fragment transplantation, cells were cultured without serum under hypoxia (1 % O2) and treated with Z-VAD-FMK. The metabolic activity of the cells was evaluated by WST-1 assay. Cell viability was determined by FACS analyses. The expression of apoptosis-related molecules was assessed by RT-qPCR and Western blot analyses.


    (Only for Reference)
Animal Research:

[7]

- Collapse
  • Animal Models: CD1 mice
  • Dosages: 10 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 93 mg/mL (198.93 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+35 %PEG 300+2%Tween 80+ddH2O
For best results, use promptly after mixing.
6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 467.49
Formula

C22H30FN3O7

CAS No. 187389-52-2
Storage powder
in solvent
Synonyms N/A
Smiles CC(C)C(C(=O)NC(C)C(=O)NC(CC(=O)OC)C(=O)CF)NC(=O)OCC1=CC=CC=C1

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you suggest an in vivo formulation of S7023 for animal studies?

  • Answer:

    For in vivo study of S7023, The IP formulation is 2% DMSO+35 % PEG 300+2% Tween 80+ddH2O up to 6 mg/ml. The gavage formula is 1%CMC-Na up to 30 mg/ml (suspensions).

  • Question 2:

    What is difference between S7023 & S8102?

  • Answer:

    Unlike S7023, S8102 does not require pretreatment with esterase for in vitro studies. This information was cited from the article: https://www.ncbi.nlm.nih.gov/pubmed/16973565.

Caspase Signaling Pathway Map

Related Caspase Products

Tags: buy Z-VAD-FMK | Z-VAD-FMK supplier | purchase Z-VAD-FMK | Z-VAD-FMK cost | Z-VAD-FMK manufacturer | order Z-VAD-FMK | Z-VAD-FMK distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID